Seminars in Hematology
Volume 43, Issue 2 , Pages 96-106 , April 2006

Treatment of Older Patients With Acute Myeloid Leukemia—New Agents

  • Alan K. Burnett

      Affiliations

    • Corresponding Author InformationAddress correspondence to Alan K. Burnett, MD, Department of Haematology, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK
    • ,
  • Unmesh Mohite

References 

  1. Lowenberg B , Zittoun R , Kerkhofs H , Jehn U , Abels J , Debusscher L , et al.   On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia (A randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group) . J Clin Oncol . 1989;7:1268–1274
  2. Wisch JS , Griffin JD , Kufe DW . Response of preleukemia syndromes to continuous infusion of low-dose H cytarabine . N Eng J Med . 1983;309:1599–1602
  3. Tilly H , Castaigne S , Bordessoule D , Sigaux F , Daniel MT , Monconduit M , et al.   Low-dose cytosine arabinoside treatment for acute non-lymphocytic leukemia in elderly patients . Cancer . 1985;55:1633–1636
  4. Roberts JD , Ershler WB , Tindle BH , Stewart JA . Low-dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia . Cancer . 1985;56:1001–1005
  5. Degos L , Castaigne S , Tilly H , Sigaux F , Daniel MT . Treatment of leukemia with low-dose ara-C (A study of 160 cases) . Semin Oncol . 1985;12:196–199
  6. Cheson BD , Japerse DM , Simon R , Friedman MA . A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes . J Clin Oncol . 1986;4:1857–1864
  7. Pinkerton PH , London B , Cowan DH . Low-dose cytosine arabinoside in acute myeloid leukemia (Remission is not due to induction of differentiation) . Am J Hematol . 1985;19:415–417
  8. Leyden M , Manoharan A , Boyd A , Cheng ZM , Sullivan J . Low dose cytosine arabinoside (Partial remission of acute myeloid leukaemia without evidence of differentiation) . Br J Haematol . 1984;57:301–307
  9. Burnett AK , Milligan D , Prentice AG , Goldstone A , McMullin MF , Wheatley K . Low dose Ara-C with or without retinoid in older patients not considered fit for intensive chemotherapy (The UK NCRI AML14 trial) . Blood . 2004;104:249a; abstr
  10. Leith CP , Chen IM , Kopecky KJ , Appelbaum FR , Head DR , Godwin JE , et al.   Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry (Identification of discordant MDR-/efflux+ and MDR1+/efflux- cases) . Blood . 1995;86:2329–2342
  11. Leith CP , Kopecky K , Godwin JE , McConnell TS , Slovak M , Chen IM , et al.  A Southwest Oncology Group study   Acute myeloid leukemia in the elderly (Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy) . Blood . 1997;89:3323–3329
  12. Leith CP , Kopecky KJ , Chen IM , Eijdems L , Slovak ML , McConnell TS , et al.   Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1 and LRP in acute myeloid leukemia (A Southwest Oncology Group study) . Blood . 1999;94:1086–1099
  13. Hart SM , Ganeshaguru K , Hoffbrand AV , Prentice HG , Mehta AB . Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia . Leukemia . 1994;8:2163–2168
  14. Hart SM , Ganeshaguru K , Scheper RJ , Prentice HG , Hoffbrand AV , Mehta AB . Expression of the human major vault protein (LRP) in acute myeloid leukemia . Exp Hematol . 1997;25:1227–1232
  15. Pirker R , Pohl G , Stranzl T , Suchomel RW , Scheper RJ , Jager U , et al.   The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia . Adv Exp Med Bio . 1999;457:133–139
  16. Solary E , Drenou B , Campos L , de Cremoux P , Mugneret F , Moreau P , et al.   Quinine as a multidrug resistance inhibitor (A phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia) . Blood . 2003;102:1202–1210
  17. List AF , Kopecky KJ , Willman CL , Spier R , Dorr R , Flaherty L , et al.   Benefit of cyclosporin (CsA) modulation of anthracycline resistance in high-risk AML (A Southwest Oncology Group (SWOG) study) . Blood . 1998;92:312; abstr
  18. Yin JAL , Wheatley K , Rees JK , Burnett AK . Comparison of ’sequential’ versus ’standard’ chemotherapy as re-induction treatment, with or without cyclosporin, in refractory/relapsed acute myeloid leukaemia (AML) (Results of the UK Medical Research Council AML-R trial) . Br J Haematol . 2001;113:713–726
  19. Boesch D , Gaveriaux C , Jachez B , Pourtier-Manzanedo A , Bollinger P , Loor F . In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC833 . Cancer Res . 1991;51:4226–4233
  20. Visani G , Milligan D , Leoni F , Chang J , Kelsey S , Marcus R , et al.   Combined action of PSC833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia . Leukemia . 2001;15:764–771
  21. Advani R , Saba HI , Tallman MS , Rowe JM , Wiernick PH , Ramek J , et al.   Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar . Blood . 1999;93:787–795
  22. Sonneveld P , Lowenberg B , Vossebeld P , Malkhandi J , Covelli A , Dekker AW . Dose-finding study of PSC833, a novel MDR reversing agent, with daunorubicin and ara-C in untreated elderly patients with acute myeloid leukemia . Blood . 1997;90:566a; abstr
  23. van der Holt B , Lowenberg B , Burnett AK , Knauf WU , Shepherd J , Piccaluga PP , et al.   The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis . Blood . 2005;106:2646–2654
  24. Burnett AK , Hills RK , Goldstone AH , Prentice AG , Milligan D , Pallis M . Attempts to modulate chemoresistance in older patients with AML using PSC-833 - Results of LRF AML14 Trial . Blood . 2003;102:614a; abstr
  25. Greenberg PL , Advani R , Tallman M , Letendre H , Saba K , Dugan K . Treatment of refractory/relapsed AML with PBSC833 plus mitroxantrone, etoposide, cytarabine (PBS-MEC) vs MEC (Randomised phase III trial (E2995) . Blood . 1999;94:383a; abstr
  26. Kolitz JE , George SL , Dodge RK , Hoke E , Hurd DD , Powell BL . Dose escalation studies of Ara-C (A), daunorubicin (D) and etoposide (E) with and without multidrug resistance (MDR) modulation with PSC-833 (P) in untreated adults with acute myeloid leukemia (AML) <60 years (Final induction results of CALGB 9621) . Blood . 2001;98:461a; abstr
  27. Baer MR , George SL , Dodge RK , O’Loughlin KL , Minderman H , Caligiuri MA . Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia (Cancer and Leukemia Group B study 9720) . Blood . 2002;100:1224–1232
  28. Lee EJ , George SL , Caligiuri M , Szatrowski TP , Powell BL , Lemke S , et al.   Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug-resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia (Results of Cancer and Leukemia Group B study 9420) . J Clin Oncol . 1999;17:2831–2839
  29. Larson RA . Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia? . Leukemia . 2003;17:488–491
  30. Oza AM . Clinical development of P glycoprotein modulations in oncology . Novartis Found Symp . 2002;243:103–115
  31. Peck RA , Hewett J , Harding MW , Wang YM , Chaturvedi PR , Bhatnagar A , et al.   Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin . J Clin Oncol . 2001;19:3130–3141
  32. Slapak CA , Dahlheimer J , Piwnica-Worms D . Reversal of multi-drug resistance with LY335979 (Functional analysis of p-glycoprotein-mediated transport activity and its modulation in vivo) . J Clin Pharmacol . 2001;(suppl):29S–38S
  33. Scheinberg DA , Tanimoto M , McKenzie S , Strife A , Old LJ , Clarkson BD . Monoclonal antibody M195 (A diagnostic marker for acute myelogenous leukemia) . Leukemia . 1989;3:440–445
  34. Jurcic JG , DeBlasio T , Dumont L , Yao T-J , Scheinberg DA . Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia . Clin Cancer Res . 2000;6:372–380
  35. Caron PC , Jurcic JG , Scott AM , Finn RD , Divgi CR , Graham MC . A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia (Specific targeting without immonogenicity) . Blood . 1994;83:1760–1768
  36. Feldman EJ , Brandwein J , Stone R , Kalaycio M , Moore J , O’Connor J , et al.   Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia . J Clin Oncol . 2005;23:4110–4116
  37. Tanimoto M , Scheinberg DA , Cordon-Cardo C , Huie D , Clarkson BD , Old LJ , et al.   Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195 . Leukemia . 1989;5:339–348
  38. Kell WJ , Burnett AK , Chopra R , Yin JA , Clark RE , Rohatiner A , et al.   A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia . Blood . 2003;102:4277–4283
  39. Zein N , Sinha AM , McGahren WJ , Ellestad GA . Calicheamicin gamma 1I (An antitumor antibiotic that cleaves double-stranded DNA site specifically) . Science . 1988;240:1198–1201
  40. Sievers EL , Appelbaum FR , Spielberger RT , Forman SJ , Flowers D , Smith FO , et al.   Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy (A phase I study of an anti-CD33 calicheamicin immunoconjugate) . Blood . 1999;93:3678–3684 abstr
  41. Sievers E , Larson R , Estey E , et al.   Final report of prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin followed by haematopoietic stem cell transplant . Blood . 2002;100:11; abstr 89a
  42. Larson RA , Boogaerts MA , Estey E , Karanes C , Stadtmauer EA , Sievers EL , et al.   Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin . Leukemia . 2002;16:1627–1636
  43. Breems DA, van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, et al  Prognostic index for adult patients with acute myeloid leukemia in first relapse . J Clin Oncol . 2005;23:1969–1978
  44. Nabhan C , Rundhaugen LM , Riley MB , Boehlke L , Jatoi M , Tallman MS . Phase II trial of gemtuzumab ozogamicin (GO) as first line therpy in acute myeloid leukemia patients age 65 or older . Blood . 2003;102:618a; abstr
  45. Petti MC , Pinazzi MB , Diverio D , Romano A , Petrucci MT , De Santis S , et al.   Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676 . Br J Haematol . 2001;115:63–65
  46. Estey E , Giles F , Beran M , O’Brien S , Pierce S , Faderl S , et al.   Experience with gemtuzumab ozogamicin (“mylotarg”) + all-trans retinoic acid in untreated acute promyelocytic leukemia . Blood . 2002;99:4222–4224
  47. Warrell RP , Berman E . Phase I and II study of fludarabine phosphate in leukemia (Therapeutic efficacy with delayed central nervous system toxicity) . J Clin Oncol . 1986;4:74–79
  48. Spriggs DR , Stopa E , Mayer RJ , Schoene W , Kufe DW . Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia (Phase I and neuropathological study) . Cancer Res . 1986;46:5953–5958
  49. Vahdat L , Wong ET , Wile MJ , Rosenblum M , Foley KM , Warrell RP . Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia . Blood . 1994;84:3429–3434
  50. Montgomery JA , Shortnacy-Fowler AT , Clayton SD , Riordan JM , Secrist JA3rd . Synthesis and biological activity of 2′-fluoro-2-halo derivatives of 9-β-D-arabinofurano-syladenine . J Med Chem . 1992;35:397–401
  51. Kantarjian HM , Gandhi V , Kozuch P , Faderl S , Giles F , Cortes J , et al.   Phase I clinical and pharmacology study of clofarabine in patients with solid and hematological cancers . J Clin Oncol . 2003;21:1167–1173
  52. Kantarjian H , Gandhi V , Cortes J , Verstovsek S , Du M , Garcia-Manero G , et al.   Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia . Blood . 2003;102:2379–2386
  53. Burnett AK , Russell N , Kell WJ , Milligan D , Culligan D . A phase 2 evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy . Blood . 2004;104:248a; abstr
  54. Faderl S , Gandhi V , O’Brien S , Bonate P , Cortes J , Estey E , et al.   Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias . Blood . 2005;105:940–947
  55. Faderl S , Gandhi V , Verstovsek S , et al.   Clofarabine plus cytarabine (ara-C) combination is active in newly diagnosed patients (pts) ≥age 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS . Blood . 2004;104:250a; abstr
  56. Faderl S , Ferrajoli A , Wierda W , et al.   Phase I study of clofarabine plus idarubicin and clofarabine plus idarubicin plus cytarabine (ara-C) in patients (pts) with relapsed and primary refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloid blast phase of chronic myeloid leukemia (CML . Blood . 2004;104:501a; abstr 1809
  57. Giles F , Thomas D , Garcia-Manero G , Faderl S , Cortes J , Verstovsek S , et al.   A phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia . Clin Cancer Res . 2004;10:2908–2917
  58. Birg F , Courcoul M , Rosnet O , Bardin F , Pebusque MJ , Marchetto S , et al.   Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages . Blood . 1992;80:2584–2593
  59. Kiyoi H , Towatari M , Yokota S , Hamaguchi M , Ohno R , Saito H , et al.   Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product . Leukemia . 1998;12:1333–1337
  60. Nakao M , Yokota S , Iwai T , Kaneko H , Horiike S , Kashima K . Internal tandem duplication of the flt3 gene found in acute myeloid leukemia . Leukemia . 1996;10:1911–1918
  61. Kottaridis PD , Gale RE , Frew ME , Harrison G , Langabeer S , Belton AA , et al.   The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy (analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 Trials) . Blood . 2001;98:1752–1759
  62. Gilliland DG , Griffin JD . The roles of FLT3 in hematopoiesis and leukemia . Blood . 2002;100:1532–1542
  63. Griffith J , Black J , Faerman C , Swenson L , Wynn M , Lu F , et al.   The structural basis for autoinhibition of FLT3 by the juxtamembrane domain . Mol Cell . 2004;13:169–178
  64. Levis M , Small D . FLT3 (IT does matter in leukemia) . Leukemia . 2003;17:1738–1752
  65. Gale RE, Hills RK, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF, et al. The relationship between FLT3 mutation status, biological characteristics and response to targeted therapy in acute promyelocytic leukemia . Blood . 2005;106:3768–3776
  66. Gale RE, Hills RK, Kottaridis PD, Srirangan S, Wheatley K, Burnett AK, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML) (An analysis of 1135 patients excluding acute promyelocytic leukemia from the UK MRC AML10 and 12 trials) . Blood . 2005;106:3658–3665
  67. Fiedler W , Mesters R , Tinnefeld H , Loges S , Staib P , Duhrsen U , et al.   A phase II clinical study of SU5416 in patients with refractory acute myeloid leukemia . Blood . 2003;102:2763–2767
  68. Giles FJ , Cooper MA , Silverman L , Karp JE , Lancet JE , Zangari M , et al.   Phase II study of SU5416-a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor-in patients with refractory myeloproliferative diseases . Cancer . 2003;97:1920–1928
  69. O’Farrell A-M , Foran JM , Fiedler W , Serve H , Paquette RL , Cooper MA , et al.   An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients . Clin Cancer Res . 2003;9:5465–5476
  70. Weisberg E , Boulton C , Kelly LM . Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412 . Cancer Cell . 2002;1:433–443
  71. Stone RM , Deangelo DJ , Klimek V , Galinsky I , Estey E , Nimer SD . Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 . Blood . 2005;105:54–60
  72. Smith BD , Levis M , Beran M , Giles F , Kantarjian H , Berg K , et al.   Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia . Blood . 2004;103:3669–3676
  73. Knapper S, Burnett AK, Kell WJ, Clark R, Craig J, Chopra R, et al: A Phase II trial of the FLT3 inhibitor CEP701 as first line treatment for older patients with acute myeloid leukaemia not considered fit for intensive chemotherapy. Proc Am Soc Hematol (abstr, submitted)
  74. De Angelo DJ , Stone RM , Heaney ML , Nimer SD , Paquette R , Bruner-Klisovic R , et al.   Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with acute myeloid leukemia (AML) bearing a FLT3 internal tandem duplication (ITD) mutation . Blood . 2004;104:496a–497a
  75. Levis M , Pham R , Smith BD , Small D . In vitro studies of a FLT3 inhibitor combined with chemotherapy (Sequence of administration is important to achieve synergistic cytotoxic effects) . Blood . 2004;104:1145–1150
  76. End DW , Smets G , Todd AV , Applegate TL , Fuery CJ , Angibaud P , et al.   Characterization of the antitumor effects of the selective farnesyl protein transfease inhibitor R115777 in vivo and in vitro . Cancer Res . 2001;61:131–137
  77. Kelland LR , Smith V , Valenti M , et al.   Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer . Clin Cancer Res . 2001;7:3544–3550
  78. Karp JE , Lancet JE , Kaufmann SH , End DW , Wright JJ , Bol K , et al.   Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias (A phase 1 clinical-laboratory correlative trial) . Blood . 2001;97:3361–3369
  79. Harousseau JL , Reiffers J , Lowenberg B , Thomas X , Huguet F , Fenaux P , et al.   Zarnestra (R115777) in patients with relapsed and refractory acute myelogenous leukemia (AML) (Results of a multicenter phase 2 study) . Blood . 2003;102:614; abstr
  80. Lancet JE , Gotlib J , Gojo I , Feldman EJ , Morris L , Thibault A , et al.   Tipifarnib (ZARNESTRA) in previously untreated poor risk AML of the elderly (Updated results of a multicenter phase 2 trial) . Blood . 2004;104249a: abstr
  81. Kurzrock R , Cortes J , Kantarjian H . Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome . Semin Hematol . 2002;39(suppl 3):20–24
  82. Feldman EJ , Cortes J , Holyoake TL , et al.   Continuous oral lonafarnib (Sarasar) for the treatment of patients with myelodysplastic syndrome . Blood . 2003;102:421a; abstr

PII: S0037-1963(06)00020-5

doi: 10.1053/j.seminhematol.2006.01.003

Seminars in Hematology
Volume 43, Issue 2 , Pages 96-106 , April 2006

Article Tools

* Image Usage & Resolution